Procumbide

Procumbide at a Glance

Procumbide is a minor iridoid glycoside of devil’s claw (Harpagophytum procumbens), the Southern African herb whose secondary storage root (tuber) is used for inflammatory and musculoskeletal complaints. It is named for the plant and is routinely listed among the herb’s characteristic iridoids, alongside the dominant harpagoside, harpagide and 8-coumaroylharpagide ^{1,2Reference 1Menghini L et al. · 2019Devil’s claw (Harpagophytum procumbens) and chronic inflammatory diseases: a concise overview on preclinical and clinical dataView study →Reference 2Mncwangi N et al. · 2012ReviewDevil’s claw — a review of the ethnobotany, phytochemistry and biological activity of Harpagophytum procumbensView study →}.

Beyond that listing there is very little to say about the isolated molecule. Procumbide has essentially no dedicated pharmacology — it is not, on the current record, the compound tested in the studies that give devil’s claw its anti-inflammatory reputation. That reputation belongs to the whole standardised extract and, within it, chiefly to harpagoside ^{3,4,5Reference 3Abdelouahab N · 2008In vitroEffect of the major glycosides of Harpagophytum procumbens (devil’s claw) on epidermal cyclooxygenase-2 (COX-2) in vitroView study →Reference 4Chrubasik S et al. · 1999RCTEffectiveness of Harpagophytum extract WS 1531 in the treatment of exacerbation of low back pain: a randomized, placebo-controlled, double-blind studyView study →Reference 5Chantre P et al. · 2000Efficacy and tolerance of Harpagophytum procumbens versus diacerhein in treatment of osteoarthritisView study →}. Procumbide’s practical role is as a co-marker of the plant’s iridoid fraction, not as an active in its own right.

A Minor Devil’s-Claw Iridoid

Devil’s claw stores a cluster of iridoid glycosides in its tuber, and procumbide is one of them. The set is dominated by harpagoside — the marker to which commercial extracts are standardised and the compound “most responsible for therapeutic activity” in reviews of the herb ^{1Reference 1Menghini L et al. · 2019Devil’s claw (Harpagophytum procumbens) and chronic inflammatory diseases: a concise overview on preclinical and clinical dataView study →} — accompanied by harpagide, 8-coumaroylharpagide, and, as a minor member, procumbide ^{1,2Reference 1Menghini L et al. · 2019Devil’s claw (Harpagophytum procumbens) and chronic inflammatory diseases: a concise overview on preclinical and clinical dataView study →Reference 2Mncwangi N et al. · 2012ReviewDevil’s claw — a review of the ethnobotany, phytochemistry and biological activity of Harpagophytum procumbensView study →}.

Two honest points define procumbide’s place in this family:

• It is a co-marker, not a driver. Procumbide is named and quantified as part of the herb’s iridoid profile, but the plant’s biological activity is ascribed to the iridoid class as a whole and, specifically, to harpagoside ^{1,2Reference 1Menghini L et al. · 2019Devil’s claw (Harpagophytum procumbens) and chronic inflammatory diseases: a concise overview on preclinical and clinical dataView study →Reference 2Mncwangi N et al. · 2012ReviewDevil’s claw — a review of the ethnobotany, phytochemistry and biological activity of Harpagophytum procumbensView study →}. When researchers dissected the iridoids’ effects on epidermal COX-2, they tested harpagoside, harpagide, 8-coumaroylharpagide and verbascoside — procumbide was not among the compounds tested ^{3Reference 3Abdelouahab N · 2008In vitroEffect of the major glycosides of Harpagophytum procumbens (devil’s claw) on epidermal cyclooxygenase-2 (COX-2) in vitroView study →}. Its pharmacology is therefore assumed from the class, not demonstrated for the molecule.
• The whole-plant caveat cuts hard here. Devil’s claw’s clinical evidence — randomised trials in low-back pain and osteoarthritis — is for standardised whole-root extracts (e.g. WS 1531, standardised to harpagoside), not for any single iridoid, least of all this one ^{4,5Reference 4Chrubasik S et al. · 1999RCTEffectiveness of Harpagophytum extract WS 1531 in the treatment of exacerbation of low back pain: a randomized, placebo-controlled, double-blind studyView study →Reference 5Chantre P et al. · 2000Efficacy and tolerance of Harpagophytum procumbens versus diacerhein in treatment of osteoarthritisView study →}. Attributing the herb’s effect to procumbide would be a mistake in both directions: the isolate has no such data, and the extract’s effect is a composite the field still standardises to harpagoside.

Stated plainly: procumbide is a genuine, characteristic devil’s-claw iridoid with minimal isolate data, and the herb’s activity is not attributed to it.

Major Natural Sources

Source	Part	Notes
Devil’s claw (Harpagophytum procumbens)	Secondary storage root (tuber)	Traded species; procumbide listed among its characteristic iridoids 1,2Reference 1Menghini L et al. · 2019Devil’s claw (Harpagophytum procumbens) and chronic inflammatory diseases: a concise overview on preclinical and clinical dataView study →Reference 2Mncwangi N et al. · 2012ReviewDevil’s claw — a review of the ethnobotany, phytochemistry and biological activity of Harpagophytum procumbensView study →
Devil’s claw (Harpagophytum zeyheri)	Root	Cheaper congener with a comparable harpagoside content but differing non-harpagoside iridoid profile 6Reference 6Kondamudi N et al. · 2016Harpagoside content in devil’s claw extractsView study →

Procumbide has not been reported as a notable constituent outside the Harpagophytum genus in the sources reviewed. The related Stachys/Betonica-type iridoids (harpagide, 8-O-acetylharpagide) do appear in other herbs such as wood betony, but procumbide is treated as a devil’s-claw iridoid.

What It's Used For

There is no body of pharmacology for isolated procumbide. What follows is deliberately short: it records the two things procumbide is associated with — quality control and the anti-inflammatory iridoid class — and, in each case, states that the evidence is not the molecule’s own.

Evidence by IndicationStrength of support · Beta

Support is an experimental score — weighted by study type (human > animal > in vitro) and volume. A beta, not a validated metric. Both rows are low by design: neither rests on data for isolated procumbide.

01Devil’s-claw quality co-markerShaky15%Named/quantified as a characteristic iridoid; no bioactivity of its own ^{1,2Reference 1Menghini L et al. · 2019Devil’s claw (Harpagophytum procumbens) and chronic inflammatory diseases: a concise overview on preclinical and clinical dataView study →Reference 2Mncwangi N et al. · 2012ReviewDevil’s claw — a review of the ethnobotany, phytochemistry and biological activity of Harpagophytum procumbensView study →}

02Anti-inflammatory (iridoid class)Shaky8%Class-level only; procumbide was not the tested compound ^{2,3Reference 2Mncwangi N et al. · 2012ReviewDevil’s claw — a review of the ethnobotany, phytochemistry and biological activity of Harpagophytum procumbensView study →Reference 3Abdelouahab N · 2008In vitroEffect of the major glycosides of Harpagophytum procumbens (devil’s claw) on epidermal cyclooxygenase-2 (COX-2) in vitroView study →}

Mechanisms

No mechanism of action has been characterised for isolated procumbide. The table records only the class context — mechanisms established for other devil’s-claw iridoids — with the explicit caveat that none has been shown for procumbide.

The load-bearing point is what the table does not contain: no row can be attributed to procumbide. The whole-extract effect is ratio-dependent across the iridoids, and even that story is written in harpagoside and harpagide, not this molecule ^{3Reference 3Abdelouahab N · 2008In vitroEffect of the major glycosides of Harpagophytum procumbens (devil’s claw) on epidermal cyclooxygenase-2 (COX-2) in vitroView study →}.

Pharmacokinetics

There are no pharmacokinetic data for procumbide. As a polar iridoid glycoside it would be expected to share the class’s characteristic poor oral bioavailability — iridoid glycosides are large, hydrophilic molecules that are absorbed poorly intact and are extensively hydrolysed by gut microbiota to their aglycones before or instead of systemic absorption. This is a class-level expectation, not a measured value for procumbide; absorption, metabolism and half-life for the isolated compound are uncharacterised.

Clinical Trials

None for isolated procumbide. The human evidence in this area is for standardised devil’s-claw root extract, not for any single iridoid — for example a randomised, placebo-controlled trial of the harpagoside-standardised extract WS 1531 in low-back-pain exacerbations ^{4Reference 4Chrubasik S et al. · 1999RCTEffectiveness of Harpagophytum extract WS 1531 in the treatment of exacerbation of low back pain: a randomized, placebo-controlled, double-blind studyView study →}, and a randomised comparison of Harpagophytum against diacerhein in hip/knee osteoarthritis ^{5Reference 5Chantre P et al. · 2000Efficacy and tolerance of Harpagophytum procumbens versus diacerhein in treatment of osteoarthritisView study →}. Procumbide is present in those extracts only as one minor constituent.

Last checked: July 2026.

Prevalence in Nature

Procumbide occurs in the secondary storage root (tuber) of devil’s claw, the plant part that carries the herb’s active iridoid fraction; it is not a constituent of the aerial parts ^{2Reference 2Mncwangi N et al. · 2012ReviewDevil’s claw — a review of the ethnobotany, phytochemistry and biological activity of Harpagophytum procumbensView study →}. It is reported for the traded species Harpagophytum procumbens and is expected in the cheaper congener H. zeyheri, whose overall harpagoside content is comparable to procumbens but whose non-harpagoside iridoid profile differs ^{6Reference 6Kondamudi N et al. · 2016Harpagoside content in devil’s claw extractsView study →} — a reminder that minor iridoids like procumbide vary with species, provenance and preparation.

Concentrations of procumbide are not quantified in the sources reviewed here; harpagoside is the iridoid that gets measured, because it is the standardisation marker ^{1,6Reference 1Menghini L et al. · 2019Devil’s claw (Harpagophytum procumbens) and chronic inflammatory diseases: a concise overview on preclinical and clinical dataView study →Reference 6Kondamudi N et al. · 2016Harpagoside content in devil’s claw extractsView study →}. Where procumbide sits in absolute or relative terms within the tuber is therefore an open figure (tracked in this molecule’s gaps note).

Discovery & Synthesis

Procumbide is documented as one of the characteristic iridoid glycosides of devil’s claw, but — unlike harpagoside, which has a well-developed literature — it has no clearly recorded first-isolation history or total synthesis in the sources reviewed. It is obtained, when needed, by extraction from Harpagophytum root as part of the iridoid fraction rather than by synthesis, and it is handled as a phytochemical marker rather than a manufactured or supplemented compound. Its name derives straightforwardly from the source species, H. procumbens.

Patents: not yet researched.

Toxicity & Safety

Procumbide carries a low flag. This reflects the absence of any specific toxicity signal rather than a positive safety dataset: the isolated molecule has not been characterised toxicologically, and the flag rests on the general tolerability of the parent herb, whose iridoids are regarded as low-toxicity constituents ^{2Reference 2Mncwangi N et al. · 2012ReviewDevil’s claw — a review of the ethnobotany, phytochemistry and biological activity of Harpagophytum procumbensView study →}.

Safety at a Glance

✅ Low / no toxicity

• Devil’s claw is generally well tolerated in customary use; its iridoids, including procumbide, are treated as low-toxicity constituents ^{2Reference 2Mncwangi N et al. · 2012ReviewDevil’s claw — a review of the ethnobotany, phytochemistry and biological activity of Harpagophytum procumbensView study →}.
• Bitter iridoids can be gastric irritants. The main tolerability issue with devil’s-claw preparations is gastrointestinal (dyspepsia); this is a herb-level, dose-related effect, not one demonstrated for procumbide specifically.
• No isolate safety data. Procumbide has not been characterised for adverse effects, interactions or reproductive toxicity as a pure compound — do not read the low flag as a tested clean bill.

Devil’s-claw root is traditionally cautioned in pregnancy (on the basis of possible uterine/oxytocic activity of the whole herb) and is generally avoided in active peptic ulcer disease because of its bitter, secretion-stimulating nature. These are herb-level cautions decided where intake happens — on the devil’s-claw monograph — and are not established findings for isolated procumbide, for which no reproductive or interaction data exist. Any drug-interaction assessment for the isolate is likewise absent from the record.

References

1. Menghini L, et al. (2019). Devil’s claw (Harpagophytum procumbens) and chronic inflammatory diseases: a concise overview on preclinical and clinical data. Phytotherapy Research. https://pubmed.ncbi.nlm.nih.gov/31273865/
2. Mncwangi N, et al. (2012). Devil’s claw — a review of the ethnobotany, phytochemistry and biological activity of Harpagophytum procumbens. Journal of Ethnopharmacology. https://pubmed.ncbi.nlm.nih.gov/22940241/
3. Abdelouahab N, Heard C (2008). Effect of the major glycosides of Harpagophytum procumbens (devil’s claw) on epidermal cyclooxygenase-2 (COX-2) in vitro. Journal of Natural Products. https://pubmed.ncbi.nlm.nih.gov/18412394/
4. Chrubasik S, et al. (1999). Effectiveness of Harpagophytum extract WS 1531 in the treatment of exacerbation of low back pain: a randomized, placebo-controlled, double-blind study. European Journal of Anaesthesiology. https://pubmed.ncbi.nlm.nih.gov/10101629/
5. Chantre P, et al. (2000). Efficacy and tolerance of Harpagophytum procumbens versus diacerhein in treatment of osteoarthritis. Phytomedicine. https://pubmed.ncbi.nlm.nih.gov/11185727/
6. Kondamudi N, Turner MW, McDougal OM (2016). Harpagoside content in devil’s claw extracts. Natural Product Communications. https://pubmed.ncbi.nlm.nih.gov/30807002/

View all 6 references▾